54013-07-9

Usage

Uses

Used in Food Industry:
2-AMINO-5-METHOXYPYRAZINE is used as a flavoring agent for its distinctive roasted or smoky flavor, enhancing the taste profiles of various foods and beverages.
Used in Medical Research:
2-AMINO-5-METHOXYPYRAZINE is studied for its potential medical applications, such as its antimicrobial and anti-inflammatory properties, indicating its possible use as a therapeutic agent in the medical industry.

InChI:InChI=1/C5H7N3O/c1-9-5-3-7-4(6)2-8-5/h2-3H,1H3,(H2,6,7)

Upstream product

• 59489-71-3 5-amino-2-bromopyrazine 
• 124-41-4 sodium methylate 
• 33332-29-5 2-amino-5-chloropyrazine 

Downstream Products

• 134510-06-8 2-hydroxy-5-methoxypyrazine 
• 1020335-77-6 phenyl (5-methoxypyrazin-2-yl)carbamate 
• 1245214-62-3 2-ethyl-N-(5-methoxypyrazin-2-yl)-4-[4-(methylsulfonyl)phenoxy]-2H-indazole-6-carboxamide 

Relevant academic research and scientific papers

Design and synthesis of a novel series of 4-heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR

Quinuclidine-containing spirooxazolines, as described in the previous report in this series, were demonstrated to have utility as α7 nicotinic acetylcholine receptor (α7 nAChR) partial agonists. In this work, the SAR of this chemotype was expanded to include an array of diazine heterocyclic substitutions. Many of the heterocyclic analogs were potent partial agonists of the α7 receptor, selective against other nicotinic receptors and the serotinergic 5HT3A receptor. (1′S,3′R,4′S)-N-(6-phenylpyrimidin-4-yl)-4H-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octan]-2-amine, a potent and selective α7 nAChR partial agonist, was demonstrated to improve cognition in the mouse novel object recognition (NOR) model of episodic memory.

Therapeutically Active Thiazolo-Pyrimidine Derivatives

A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES

A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin- 2 - yl -pyridin- 2 -yl -amine and pyrazine - 2 - yl -pyrimidin- 4 - yl -amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1 ) kinase function The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1. that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or Il inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisiπq radiation. wherein: -X= is independently -CRA5= or -N=; and the rest of the substituents are as specified in the claims.

Studies on pyrazines, Part 39.1 Synthesis and acidic hydrolysis of 2-hydroxy-5-methoxypyrazine

2-Hydroxy-5-methoxypyrazine was synthesised in a three-step reaction sequence starting from aminopyrazine. The product was extensively destroyed on acidic workup without forming 2,5-dihydroxypyrazine.

COMPOUNDS AND THERAPEUTICAL USE THEREOF

Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.